Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.39 |
| ▸ | VCAM1 | P19320 | 5/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3646610 | 0.84 | GPR35 (0.48) | TSHRMAPTALDH1A1TDP1HSD17B10 | |
| SCHEMBL3824283 | 0.82 | TSHR (0.48) | KIF18AVCAM1TSHRMAPK1ALDH1A1 | |
| SCHEMBL3609619 | 0.79 | GAA (0.40) | ALDH1A1MEN1HTTKMT2ATDP1 | |
| SCHEMBL6518952 | 0.78 | GPR35 (0.53) | VCAM1TSHRMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL11333385 | 0.77 | VCAM1 (0.39) | VCAM1TSHRMAPTALDH1A1TDP1 | |
| SCHEMBL11688142 | 0.76 | FFAR4 (0.40) | VCAM1LMNAMAPTALDH1A1TDP1 | |
| SCHEMBL11690992 | 0.76 | KIF18A (0.42) | KIF18AVCAM1TSHRMAPK1LMNA | |
| SCHEMBL5462320 | 0.76 | GPR35 (0.47) | VCAM1TSHRMAPK1LMNAMAPT | |
| SCHEMBL18829958 | 0.76 | CYP1A2 (0.55) | VCAM1TSHRMAPK1LMNAMAPT | |
| SCHEMBL27544319 | 0.74 | NSD2 (0.43) | KIF18AVCAM1TSHRMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1470114-B1 | PEPTIDE NUCLEIC ACID OLIGOMERS FROM 1-BENZENESULFONYL-3-AMINO ACID SIDE CHAIN-4-(2-NUCLEOBASE(ACETYL))-PIPERAZIN-2-ONES | PANAGENE INC (KR) | 2009-08-19 | — | — | EP | disclosed |
| CN-100351243-C | Peptide nucleic acid oligomers from 1-benzenesulfonyl-3-amino acid side chain-4- (2-nucleobase acetyl) -piperazin-2-one | PANAGENE INC (KR) | 2007-11-28 | — | — | CN | disclosed |
| US-7022851-B2 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2006-04-04 | — | — | US | disclosed |
| CN-1642923-A | Peptide nucleic acid oligomers from 1-benzenesulfonyl-3-amino acid side chain-4-(2-nucleobase(acetyl))-piperazin-2-ones | PANAGENE INC (KR) | 2005-07-20 | — | — | CN | disclosed |
| EP-1470114-A4 | PEPTIDE NUCLEIC ACID OLIGOMERS FROM 1-BENZENESULFONYL-3-AMINO ACID SIDE CHAIN-4-(2-NUCLEOBASE(ACETYL))-PIPERAZIN-2-ONES | PANAGENE INC (KR) | 2005-05-11 | — | — | EP | disclosed |
| EP-1470114-A1 | PEPTIDE NUCLEIC ACID OLIGOMERS FROM 1-BENZENESULFONYL-3-AMINO ACID SIDE CHAIN-4-(2-NUCLEOBASE(ACETYL))-PIPERAZIN-2-ONES | Panagene, Inc. (KR) | 2004-10-27 | — | — | EP | disclosed |
| US-20030195332-A1 | PNA monomer and precursor | PANAGENE, INC. (KR) | 2003-10-16 | — | — | US | disclosed |
| WO-2003062212-A1 | PEPTIDE NUCLEIC ACID OLIGOMERS FROM 1-BENZENESULFONYL-3-AMINO ACID SIDE CHAIN-4-(2-NUCLEOBASE(ACETYL))-PIPERAZIN-2-ONES | PANAGENE, INC. (US) | 2003-07-31 | — | — | WO | disclosed |
| US-4008208-A | Compositions having inhibited ability to promote platelet aggregation or fibrin clot formation | THE UPJOHN COMPANY (US) | 1977-02-15 | — | — | US | disclosed |
| US-3975371-A | Aromatic azo sulfonylnitrene compounds | THE UPJOHN COMPANY (US) | 1976-08-17 | — | — | US | disclosed |
| US-3954583-A | Photochemical process | THE UPJOHN COMPANY (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195332-A1 | PNA monomer and precursor | RNGTT, NGLY1, NCL | KIF18A 4811/4885VCAM1 1646/4885TSHR 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.